Skip to content
Screener

Discontinued — last reported Q4 '21

Net margin at other companies

Eli Lilly logo
Eli LillyLLY
33.5%+7.6pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
21.5%-3.5pp
Amgen logo
AmgenAMGN
23%+4.0pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
27.9%-3.5pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-921.5%+161pp
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-4,987.4%-8,966pp

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.16B+148%
Enterprise value$1.08B+174%

Profitability

See full
Operating margin-358.7%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Calculated from Cullinan Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Cullinan Therapeutics, Inc.’s 10-K, filed March 9, 2023. Open the filing →

Filed
Mar 9, 2023
Fiscal year
FY2022
Accession
0000950170-23-006839

FAQ

What is Cullinan Therapeutics, Inc.'s net margin?
Cullinan Therapeutics, Inc. (CGEM) reported net margin of -346.1% in Q4 2021.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.

Ask your AI about Cullinan Therapeutics, Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude